Portola Pharma misses by $0.10, misses on revs
- Reports Q2 (Jun) loss of $1.61 per share, $0.10 worse than the Capital IQ Consensus of ($1.51); revenues rose 5.8% year/year to $4.01 mln vs the $6.35 mln Capital IQ Consensus.
- This includes $1.7 million in collaboration and license revenue earned under Portola's collaboration and license agreements with Bristol-Myers Squibb Company, Pfizer, Bayer Pharma, Janssen Pharmaceuticals and Daiichi Sankyo, as well as $2.2 million from initial sales of Andexxa in the U.S. under the Company's Early Supply Program launched in May 2018, and $33,000 in product revenue from sales of Bevyxxa, which launched in the U.S. in January 2018.
No comments:
Post a Comment